Business
Medistim ASA - Status on share buyback
Medistim ASA - Status on share buyback
About this update from Medistim Asa
Oslo, 16h of April 2025: Reference is made to the stock exchange announcementmade by Medistim ASA on 11 March 2025 of the launch of Medistim's program torepurchase up to 70,000 of the Company's shares in open market transactionsfora total amount of up to NOK 35,000,000 during the period from 11 March 2025,until no later than 7 May 2025, pursuant to an agreement with DNB Markets. Forthe period from and including 11 March 2025, through 16th of April 2025, theCompany purchased a total of 66,460 shares at an average price of NOK 179.5465per share, all purchased as ordinary market purchases on Euronext Oslo Børs.Please find below the transaction overview:-----------------------------------------------------------------------------Date / Aggregated daily volume (#shares) / Weighted average share price perday(NOK) / Total daily transaction value (NOK)Date: 14 April 2025. Number of share: 1,789. Avg price: NOK 162.8382 pershareDate: 15 April 2025. Number of share: 1,673. Avg price: NOK 161.4304 pershareDate: 16 April 2025. Number of share: 1,616. Avg price: NOK 161.6906 pershareTotal for this period:5,078 shares purchased at average share price of NOK 162.0091 per share. Totaltransaction value was NOK 822,682.61.Previously disclosed buybacks under the program:61,382 shares purchased at average share price of NOK 180.9973 per share.Totaltransaction value was NOK 11,109,979.14-----------------------------------------------------------------------------The issuer's holding of own shares: Following the completion of the above transactions, Medistim owns a total of89,577 of own shares (including 23,117 shares owned prior to the launch of thebuyback program), corresponding to 0.4884 % of Medistim's share capital.Appendix: An overview of all transactions made under the buyback program that have beencarried out during the above-mentioned time period is attached to this reportand available at www.newsweb.no.For further information, please contact:Thomas Jakobsen, Chief Financial Officer, phone: +47 906 59 940Mail: [email protected] is information that Medistim is obliged to make public pursuant to the EUMarket Abuse Regulation and subject to the disclosure requirements pursuant toSection 5-12 of the Norwegian Securities Trading Act.https://newsweb.oslobors.no/message/643962